Welcome to our dedicated page for KONINKLIJKE PHILIPS NV SEC filings (Ticker: RYLPF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KONINKLIJKE PHILIPS NV's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KONINKLIJKE PHILIPS NV's regulatory disclosures and financial reporting.
Koninklijke Philips N.V. reported a strong turnaround in 2025, moving from a net loss of EUR 698 million in 2024 to net income of EUR 897 million, with diluted EPS from continuing operations at EUR 0.93. Sales were EUR 17.8 billion with 2% comparable growth, while the Adjusted EBITA margin improved to 12.3% from 11.5%, reflecting better gross margins and EUR 0.8 billion of productivity savings in 2025.
In Q4 2025, comparable sales grew 7% and Adjusted EBITA margin rose to 15.1%, supported by double‑digit growth in Personal Health and solid performance in Connected Care. Free cash flow reached EUR 512 million for the year and EUR 1.2 billion in Q4, despite a EUR 1,025 million cash payment for Respironics recall‑related settlements. Philips proposes a 2025 dividend of EUR 0.85 per share, and guides for 2026 comparable sales growth of 3%–4.5%, an Adjusted EBITA margin of 12.5%–13.0%, and free cash flow of EUR 1.3–1.5 billion. The company also laid out 2026–2028 mid‑term targets, including mid‑single‑digit comparable sales growth and a mid‑teens Adjusted EBITA margin by 2028.
Koninklijke Philips N.V. reported Q3 2025 results showing continued momentum: comparable order intake grew 8% and group sales were EUR 4.3 billion, up 3.3% on a comparable basis. Income from operations was EUR 330 million. The adjusted EBITA margin rose 50 bps to 12.3% as higher sales, mix and productivity more than offset tariff headwinds.
Operating cash flow was EUR 327 million with free cash flow of EUR 172 million. Segment trends were mixed: Diagnosis & Treatment comparable sales grew 1.3% with margin at 11.8% (down 80 bps), Connected Care grew 5.1% with margin up 410 bps to 11.4%, and Personal Health grew 10.9% with margin at 17.1%.
Philips reiterated its full‑year 2025 outlook: comparable sales growth of 1%–3%, adjusted EBITA margin of 11.3%–11.8% now expected toward the upper end, and free cash flow of EUR 0.2–0.4 billion, which includes the EUR 1,025 million settlements paid in Q1 2025. The outlook excludes ongoing Philips Respironics‑related proceedings.